



PATENT  
Attorney Docket 038073-5002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Mark Player <i>et al.</i>	)	
	)	
Application No. 10/673,521	)	Art Unit: 1614
	)	
Filed: September 30, 2003	)	Examiner: Not Assigned
	)	
For: 4,6-Diaminosubstituted-2-[Oxy or Aminoxy]-	)	
[1,3,5]Triazines as Protein Tyrosine Kinase	)	
Inhibitors	)	

**INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. § 1.56 and § 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO-1449 forms. This Information Disclosure Statement is being filed, to the best of the undersigned's knowledge, before the mailing date of a first Office Action on the merits for the above-referenced application. Accordingly, Applicants do not believe that a fee is due with the filing of this paper.

With the except of U.S. Patent Applications and U.S. Patents, copies of the documents are attached. Applicants respectfully request that the Examiner consider the listed documents and evidence that consideration by making appropriate notations on the attached form. This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute prior art. If the Examiner applies any one of the documents as prior art against any claim in the application, and Applicants determine that the cited document does not constitute prior art under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such document.


Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

**Except** for issue fees payable under 37 C.F.R. § 1.18, the Commissioner is hereby authorized by this paper to charge any additional fees during the entire pendency of this application including fees due under 37 C.F.R. § 1.16 and § 1.17 which may be required,

including any required extension of time fees, or credit any overpayment to Deposit Account No. 50-0310. This paragraph is intended to be a **constructive petition for extension of time** in accordance with 37 C.F.R. § 1.136(a)(3).

Dated: **March 3, 2004**  
Morgan, Lewis & Bockius LLP  
Customer No. **09629**  
1111 Pennsylvania, N.W.  
Washington, D.C. 20004  
Tele: 202-739-3000  
Fax: 202-739-3001

Respectfully submitted,  
**Morgan, Lewis & Bockius LLP**

  
\_\_\_\_\_  
Gregory T. Lowen  
Registration No. 46,882  
Direct Dial: 202-739-5915

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

PTO Form 1449

Attorney Docket  
038073-5002Application No.  
10/673,521Applicant: Mark Player *et al.*

Page 1 of 2

Filing Date: September 30, 2003

Group Art Unit: 1614

**U.S. PATENT DOCUMENTS**

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
	aa	2002/0065270	05/30/2002	Moriarty <i>et al.</i>	514	218	12/22/2000
	ab	3,563,971	02/16/1971	Wood <i>et al.</i>	260	93.7	09/26/1968
	ac	4,816,064	03/28/1989	Konno <i>et al.</i>	504	234	11/20/1986
	ad	5,153,245	10/06/1992	Cipolli <i>et al.</i>	524	100	09/09/1991
	ae	5,304,646	04/19/1994	Cipolli <i>et al.</i>	544	204	04/22/1993
	af	5,429,949	07/04/1995	Radosevich <i>et al.</i>	435	252.1	02/22/1994
	ag	5,508,193	04/16/1996	Mandelbaum <i>et al.</i>	435	253.3	08/31/1993
	ah	5,629,382	05/13/1997	Cipolli <i>et al.</i>	525	158	09/16/1994
	aj	5,811,081	09/22/1998	Fuso <i>et al.</i>	424	59	09/27/1995
	ak	6,100,254	08/08/2000	Budde <i>et al.</i>	514	221	10/10/1997
	al	6,235,746	05/22/2001	Davis <i>et al.</i>	514	275	02/16/1999
	am	6,284,522	09/04/2001	Wackett <i>et al.</i>	435	262.5	10/23/1995
	an	6,342,395	01/29/2002	Hammock <i>et al.</i>	436	518	04/22/1998
	ao	6,346,625	02/12/2002	Karabelas <i>et al.</i>	548	312.1	01/20/2000
	ap	6,383,790	05/07/2002	Shokat	435	194	01/11/2000
	aq	6,395,562	05/28/2002	Hammock <i>et al.</i>	436	518	09/04/1998

**FOREIGN PATENT DOCUMENTS**

		Document No.	Date	Country	Class	Sub-Class	Translation
	ar	WO 93/12094	06/24/1993	PCT			
	as	WO 95/05366	02/23/1995	PCT			
	at	WO 96/06836	03/07/1996	PCT			
	au	WO 97/03642	02/06/1997	PCT			
	av	WO 97/03643	02/06/1997	PCT			
	aw	WO 97/35580	10/02/1997	PCT			
	ax	WO 97/37660	10/16/1997	PCT			
	ay	WO 99/01442	01/14/1999	PCT			
	az	WO 00/18759	04/06/2000	PCT			
	ba	WO 00/32575	06/08/2000	PCT			
	bb	WO 00/41526	07/20/2000	PCT			
	bc	WO 00/43369	07/27/2000	PCT			
	bd	WO 00/48004	08/17/2000	PCT			
	be	WO 00/67900	11/16/2000	PCT			
	bf	WO 00/73276	12/07/2000	PCT			
	bg	WO 00/78757	12/28/2000	PCT			

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION**

(Use several sheets if necessary)

**PTO Form 1449**Attorney Docket  
**038073-5002**Application No.  
**10/673,521**Applicant: **Mark Player *et al.*****Page 2 of 2**Filing Date: **September 30, 2003**Group Art Unit: **1614****FOREIGN PATENT DOCUMENTS**

		Document No.	Date	Country	Class	Sub-Class	Translation
	bh	WO 01/47897 ✓	07/05/2001	PCT			
	bi	WO 01/47921 ✓	07/05/2001	PCT			
	bj	WO 01/58899 ✓	08/16/2001	PCT			
	bk	WO 01/94346 ✓	12/13/2001	PCT			
	bl	0 365 818 A1 ✓	05/02/1990	Europe			
	bm	0 475 364 A1 ✓	03/18/1992	Europe			
	bn	0 475 368 A2 ✓	03/18/1992	Europe			
	bo	0 627 428 A1 ✓	12/07/1994	Europe			
	bp	0 634 412 A1 ✓	01/18/1995	Europe			
	bq	GB 2 311 788 A ✓	10/08/1997	Great Britain			
	br	3-241069 ✓	10/28/1991	Japan			
	bs	3-241089 ✓	10/28/1991	Japan			

Examiner

Date Considered

**Examiner:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.